Sunshine Biopharma Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed by Sunshine Biopharma Inc., a Colorado corporation with principal executive offices in Quebec, Canada. The report covers events occurring on February 9, 2022. The company is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a corporate action rather than financial performance results.
Material Changes
- Reverse Stock Split: Effective February 9, 2022, the company executed a reverse stock split at a ratio of 1-for-200 (one new share issued for every 200 old shares).
- Corporate Governance: An Amendment to the Articles of Incorporation was filed with the Colorado Secretary of State on February 8, 2022, to re-establish capitalization following the split.
- Approval: The action was approved by the Board of Directors and shareholders holding a majority of issued and outstanding voting securities.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, or contingencies beyond the execution of the stock split.
Key Facts for Investor Verification
- Confirm the post-split share count and par value adjustments in subsequent filings.
- Verify the trading symbol and exchange status following the 1-for-200 split.
- Review the attached Amendment to Articles of Incorporation (Exhibit 3.7) for specific capitalization details.
- Check for any delisting notices or compliance issues that may have prompted the reverse split.